YD Bio Announces FDA Grant of INTERACT Meeting Request for YDB-LMSCEV-001, an Investigational Extracellular Vesicle Candidate for Dry Eye Disease

YD Bio has announced that the U.S. FDA has granted its request for an INTERACT meeting for YDB-LMSCEV-001, an investigational biologic eye drop for moderate-to-severe dry eye disease. The FDA will provide early written regulatory feedback by January 4, 2027, to guide the development of this extracellular vesicle-based therapy. This feedback will help YD Bio finalize manufacturing and preclinical plans before a formal pre-Investigational New Drug (pre-IND) meeting.